1. Sanofi and Aqemia Reach $140 Million Agreement to Jointly Focus on Small Molecule Discovery

Sanofi Partners with French Startup Aqemia, Which Uses Quantum Physics Algorithms and Generative AI to Accelerate Drug Discovery. The Deal, Worth Up to $140 Million, Aims to Discover Small Molecules Across Multiple Therapeutic Areas. Aqemia’s Approach Impressed Sanofi, Building on an Existing Relationship. The Partnership Seeks to Expand Their Respective Expertise and Support Sanofi in Leveraging Aqemia’s Unique Technology to Discover New Chemical Entities.

2. Zhiyun Health enters into strategic cooperation agreement with China Resources Shenghuo, a wholly-owned subsidiary of China Resources Sanjiu

Zhiyun Health and China Resources Sanjiu's subsidiary, China Resources Shenghuo, Sign Strategic Cooperation Agreement to Jointly Focus on Chronic Disease Field, with Emphasis on Cardiovascular and Endocrine Diseases. China Resources Sanjiu is a State-Owned Pharmaceutical Giant with Multiple Products Exceeding 100 Million in Sales.

3. Shanghai Qianqiu Intelligent Technology Co., Ltd. Secures Multi-Million Angel Round Financing for Product Development and Market Expansion

On March 6, 2024, Shanghai Qianqiu Intelligent Technology Co., Ltd., a digital therapeutics company specializing in mental rehabilitation, recently completed an angel round of financing worth tens of millions. This round was led by Ruizi Venture Capital, with Zhonglan Innovation serving as the long-term financial advisor. The funds will be used for product development and market expansion. Founded in 2021, Qianqiu Intelligent provides a full-process digital therapeutic solution based on VR technology for the preliminary diagnosis, rehabilitation training, and post-training evaluation of children with autism. The founder of Qianqiu Intelligent, Chunbo Shi, graduated from Waseda University in Japan and studied under a well-known scholar in the field of autism rehabilitation. Supported by top universities in Shanghai and several Class III, Grade A hospitals, the team has designed digital therapeutic solutions based on classical intervention methods such as behaviorism therapy. These solutions have completed initial validation and obtained relevant intellectual property rights, with medical device registration permits currently being applied for.

4. Grand Pharmaceutical Group Limited's Innovative Drug, Introduced for Nearly 70 Million, FDA Approved

TaiNew Drug's Introduced Clobetasol Propionate Ophthalmic Suspension Receives FDA Approval for Treating Post-Ophthalmic Surgery Inflammation and Pain. It Offers Advantages Such as Rapid, Sustained, Safe, and Effective Relief with Low Dosage Frequency, Good Tolerance, and Can Significantly Improve Patient Compliance. This is the First New Ophthalmic Steroid Medication in 15 Years.

5. Nalu Medical Completes $85 Million Series E Financing to Accelerate Commercial Growth and Expand Clinical and Health Economic Evidence

On March 6, 2024, Nalu Medical, a medical device company, announced the completion of a $20 million incremental equity Series E financing round, supported by B Capital. This brings the total amount of this round to $85 million, led by Novo Holdings, with $65 million completed at the end of December 2023. All existing investors also participated in this round: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners. The company plans to use the funds to accelerate commercial growth, expand clinical and health economic evidence, and continue product development and operational scaling.

6. Dashing City Completes Tens of Millions of Yuan in A+ Round Financing, Building a World-Leading One-Stop Color Contact Lens Supply Chain

Shenzhen Dashicheng Optical Technology Co., Ltd. Completes Tens of Millions of Yuan in A+ Round Financing, Led by Shenzhen Capital Group, to Expand Production Lines for Cosmetic Contact Lenses, Develop New Products and Materials, and Implement Global Layout. Dashicheng is a medical device company specializing in colored contact lenses and has obtained FDA registration certification and National High-tech Enterprise certification. The cosmetic contact lens market continues to grow in size, but there is an insufficient supply of compliant manufacturers in China. Dashicheng is committed to building an internationally leading one-stop supply chain for cosmetic contact lenses.